About
Cancer Treatments with Companion Diagnostics
Areas of Focus
Categories
DiagnosticsSmall Molecule Pharmaceutical
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
286
By Phase
PHASE1: 1PHASE2: 4PHASE1/PHASE2: 2
By Status
COMPLETED: 3SUSPENDED: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05571969Lead Sponsor
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
PHASE1Suspended
40 participants
Started: Feb 20, 2023 · Completed: Dec 31, 2025
NCT04796324Lead Sponsor
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
PHASE2Suspended
60 participants
Started: Mar 1, 2021 · Completed: Nov 1, 2025
NCT03878849Lead Sponsor
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
PHASE2Recruiting
40 participants
Started: Apr 15, 2019 · Completed: Sep 30, 2027
NCT03877796Lead Sponsor
Clinical Pre-screening Protocol for Ovarian Cancer
N/AActive, not recruiting
60 participants
Started: Apr 11, 2019 · Completed: Dec 31, 2026
NCT03643107Lead Sponsor
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
PHASE2Completed
15 participants
Started: Oct 17, 2018 · Completed: Aug 1, 2022
Locations (1)
Headquarters
Hørsholm, Denmark
Map
Loading map...